BioDuro establishes joint manufacturing venture with Cenra
Lucy Batizovsky | March 6, 2026 | News story | Manufacturing and Production |Â Â BioDuro, Cenra API Solutions, manufacturingÂ
BioDuro, a Contract Research, Development and Manufacturing Organisation (CRDMO), has established a joint venture with Cenra API Solutions, also known as Chunghwa Chemical Synthesis & Biotech (CCSB).
Cenra, a pharmaceutical chemical manufacturer in Taiwan founded in 1964, has added its Taipei campus to BioDuro’s global network.
The Taipei campus houses ten GMP API production lines, producing an annual API output of up to 200 metric tonnes and has been successfully inspected by the US FDA, EMA, Japan’s PMDA, and Taiwan’s TFDA.
BioDuro will integrate its work in early-stage drug development with Cenra’s work in commercial-scale GMP API manufacturing in the venture, to provide global clients an end-to-end API solution.
Armin Spura, CEO of BioDuro, said the venture will strengthen the resilience of both companies’ global supply chain and minimise the risk of technology-transfers.
Spura said: “This collaboration allows us to provide customers with truly integrated services and a drug substance solution that spans discovery chemistry, process R&D, regulatory starting materials, advanced intermediates and clinical- to commercial-scale API production, both inside and outside mainland China, accelerating the advance of innovative therapies to market, for patients worldwide.”
Cenra, part of the CENRA Group, was the first API manufacturer in Taiwan to receive US FDA approval. The company is focused on the development and manufacture of high-value and complex APIs, serving customers in over 50 countries.
BioDuro, an Advent portfolio company, is headquartered in Irvine, California, and employs more than 2,000 scientists specialising in small- and large-molecule discovery, development, and manufacturing.
Related Content
BioDuro and Atombeat partner to accelerate AI-powered peptide drug discovery
BioDuro and Atombeat have announced a partnership to launch an artificial intelligence (AI)-driven platform designed …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
CARBOGEN AMCIS manufacturing license advances services in China
Swiss pharma manufacturing company, CARBOGEN AMCIS, has announced that its facility in Shanghai, China, has …
